LGC expands SARS-CoV-2 molecular solutions to full genome coverage
Expansion allows for compatibility with any SARS-CoV-2 assay target, while maintaining safety features
Read MoreNews
To contact the press office please email or call +44 7408 850 514
LGC acquires The Native Antigen Company, strengthening its offer to the IVD sector
Acquisition strengthens LGC’s existing product offering to IVD sector, which includes quality assurance tools, immunoassay reagents and disease state plasma.
Read MoreNML response to the Research and Development Roadmap
The National Measurement Laboratory (NML), hosted at LGC, welcomes the publication of the UK government’s Research and Development (R&D) Roadmap with its ongoing commitment to increased investment in R&D to cement the UK’s world-leading position within science and research and support the individuals behind it.
Read MoreThe importance of standardisation of diagnostic measurements in the COVID-19 pandemic
Dr Jim Huggett, Principal Scientist at the NML at LGC, recently answered some of our questions around why standardised measurement is so important to medicine.
Read MoreLGC food forensic expert honoured by Queen’s University
A leading expert in food safety and authenticity, and a longtime partner of IGFS, Michael Walker has received an honorary professorship from Queen’s University Belfast.
Read MoreLGC and Q2 Solutions announce global bioanalytical strategic partnership
Will each contribute extensive experience and capabilities in small and large molecule bioanalysis to support customer-centric approach
Read MoreNew £1.3 million national research programme to evaluate coronavirus tests in hospitals, GP surgeries and care homes
Research programme brings together experts who are highly experienced in evaluating diagnostic tests and generating robust evidence required for a test to be used in the NHS
Read MoreCOVID-19 recovery trials: Dexamethasone and standardisation
Dexamethasone has undergone study by a team of scientists at Oxford University as part of their Recovery trial.
Read MoreLGC expands SARS-CoV-2 serology offering with 11-member positive-patient Performance Panel
Panel demonstrates a range of SARS-CoV-2 antibody reactivity
Read MoreLGC announces changes to its Executive Leadership Team
These changes follow recent strong trading performance and further strategy endorsement by Cinven and Astorg, LGC’s new shareholders.
Read MoreLGC scientists support investigations into unlicensed ‘medicines’
LGC’s Teddington-based Medicines Testing Team supported the MHRA investigation in 2015, testing samples (all of which proved negative) for the presence of vitamin D2.
Read MoreOliX Pharmaceuticals signs agreement with LGC to accelerate production of asymmetric siRNA for the treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration
LGC will produce active pharmaceutical ingredients for preclinical and clinical study of OLX301D programme.
Read More